vs
Side-by-side financial comparison of TuHURA Biosciences, Inc. (HURA) and Alaunos Therapeutics, Inc. (TCRT). Click either name above to swap in a different company.
Alaunos Therapeutics, Inc. produced more free cash flow last quarter ($-3.0M vs $-5.6M).
Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel T cell receptor (TCR) immunotherapies for the treatment of hard-to-treat solid tumors. The firm focuses on advancing precision oncology candidates targeting shared tumor antigens, serving global oncology patient populations via internal R&D and cross-sector partnerships.
HURA vs TCRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $3.0K |
| Net Profit | $-6.8M | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | — | -40.0% |
| Net Profit YoY | -12.8% | -20.5% |
| EPS (diluted) | $-0.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $0 | $3.0K | ||
| Q3 25 | $0 | $0 | ||
| Q2 25 | $0 | $0 | ||
| Q1 25 | $0 | $2.0K | ||
| Q4 24 | — | $5.0K | ||
| Q3 24 | $0 | $0 | ||
| Q2 24 | — | $4.0K | ||
| Q1 24 | $0 | $1.0K |
| Q4 25 | $-6.8M | — | ||
| Q3 25 | $-7.1M | $-1.2M | ||
| Q2 25 | $-9.5M | $-1.1M | ||
| Q1 25 | $-6.7M | $-1.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-5.6M | $-1.1M | ||
| Q2 24 | — | $-1.1M | ||
| Q1 24 | $-4.8M | $-1.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -54600.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -29150.0% | ||
| Q1 24 | — | -174200.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -53650.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -28225.0% | ||
| Q1 24 | — | -168200.0% |
| Q4 25 | $-0.13 | — | ||
| Q3 25 | $-0.14 | $-0.55 | ||
| Q2 25 | $-0.21 | $-0.63 | ||
| Q1 25 | $-0.15 | $-0.67 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.54 | $-0.70 | ||
| Q2 24 | — | $-0.71 | ||
| Q1 24 | $-0.40 | $-1.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.6M | $1.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $20.9M | $2.2M |
| Total Assets | $27.4M | $3.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.6M | $1.4M | ||
| Q3 25 | $2.7M | $1.9M | ||
| Q2 25 | $8.5M | $2.9M | ||
| Q1 25 | $6.2M | $319.0K | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | $3.0M | $1.7M | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | $6.4M | $4.1M |
| Q4 25 | $20.9M | $2.2M | ||
| Q3 25 | $16.8M | $2.8M | ||
| Q2 25 | $19.4M | $3.7M | ||
| Q1 25 | $9.9M | $1.1M | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | $-2.8M | $2.7M | ||
| Q2 24 | — | $3.8M | ||
| Q1 24 | $-6.1M | $4.8M |
| Q4 25 | $27.4M | $3.0M | ||
| Q3 25 | $25.7M | $3.7M | ||
| Q2 25 | $34.6M | $4.7M | ||
| Q1 25 | $14.6M | $2.1M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | $4.1M | $3.5M | ||
| Q2 24 | — | $4.7M | ||
| Q1 24 | $7.4M | $6.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $-2.9M |
| Free Cash FlowOCF − Capex | $-5.6M | $-3.0M |
| FCF MarginFCF / Revenue | — | -98900.0% |
| Capex IntensityCapex / Revenue | — | 3266.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $-2.9M | ||
| Q3 25 | $-11.1M | $-844.0K | ||
| Q2 25 | $-6.2M | $-701.0K | ||
| Q1 25 | $-4.7M | $-772.0K | ||
| Q4 24 | — | $-5.0M | ||
| Q3 24 | $-1.9M | $-781.0K | ||
| Q2 24 | — | $-1.7M | ||
| Q1 24 | $-3.8M | $-1.9M |
| Q4 25 | $-5.6M | $-3.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-6.3M | — | ||
| Q1 25 | $-4.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -98900.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 3266.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
